Faith E. Davies, MD, discusses the overarching goals of the Multiple Myeloma Call-to-Action, unmet needs that this plan seeks to alleviate, and ways in which all medical professionals could adopt these tenets into their practice to achieve global change in the care of patients with multiple myeloma.
Moderna and Merck recently finished a phase 2 trial for personalized mRNA vaccines for melanoma patients. The vaccine uses genetic material from a person’s tumor to develop a vaccine that teaches a person’s immune system to identify cells that match that tumor, attacking those cells before they have a chance to grow.
Pembro Benefits in mTNBC Regardless of Chemo Type medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.